Yang et al. (2015) conjugated biotinylated anti-HER2 affibodies to pre-formed phospholipid nanobubbles via streptavidin-biotin bridging, producing targeted ultrasound contrast agents for HER2-overexpressing breast tumors, with peak intensities of 104.5 dB and high tumor selectivity [66]. This evidence concerns the gene ERBB2 and neoplasm.